Table 1.
Antiproliferative effect of CLX and MMC, alone and in co-administration at 48 h, in bladder cancer cell lines
| |
UMUC3 |
UMUC-3- CX |
5637 |
5637 si-CX |
TCC sup |
J82 |
|---|---|---|---|---|---|---|
| EC50 (μM) | ||||||
|
CLX |
14.2 ± 0.7 |
16.3 ± 0.8 |
> 50 |
> 50 |
15.7 ± 0.50 |
11.6 ± 0.31 |
|
MMC |
1.69 ± 0.09 |
13.0 ± 1.0 |
0.93 ± 0.04 |
0.62 ± 0.05 |
0.83 ± 0.07 |
0.64 ± 0.09 |
|
CLX 1 μM + MMC |
1.54 ± 0.1 |
6 ± 0.3 |
1.46 ± 0.10 |
0.59 ± 0.03 |
0.74 ± 0.08 |
0.48 ± 0.03 |
|
CLX 5 μM + MMC |
1.75± 0.07 |
5.7 ± 0.2 |
1.31± 0.06 |
0.47 ± 0.01 |
0.68 ± 0.04 |
1.04 ± 0.10 |
| CLX 10 μM + MMC | 1.9 ± 0.1 | 4 ± 0.18 | 1.68 ± 0.11 | 1.01 ± 0.20 | 1.08 ± 0.20 | 1.09 ± 0.10 |
EC50 = the concentration of a compound where 50% of its maximal effect is observed.
The EC50 values were obtained from non-linear iterative curve fitting by Prism v.3.0, GraphPad software.
Compounds were tested at escalating doses, starting from 0.1 μM to 50 μM. Results are expressed as EC50.